Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis

There is solid epidemiologic evidence linking psoriasis and psoriatic arthritis (PsA) to cardiovascular risk factors and an increased risk of developing cardiovascular disease. Chronic inflammation, with shared pathways and cytokines common to metabolic syndrome, atherosclerosis and psoriasis, might...

Full description

Bibliographic Details
Main Author: Lluís Puig
Format: Article
Language:English
Published: MDPI AG 2017-12-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/19/1/58
id doaj-87c4121c8a734155b03ef5e0aeab4811
record_format Article
spelling doaj-87c4121c8a734155b03ef5e0aeab48112020-11-24T23:44:14ZengMDPI AGInternational Journal of Molecular Sciences1422-00672017-12-011915810.3390/ijms19010058ijms19010058Cardiometabolic Comorbidities in Psoriasis and Psoriatic ArthritisLluís Puig0Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Sant Quintí 89, 08041 Barcelona, SpainThere is solid epidemiologic evidence linking psoriasis and psoriatic arthritis (PsA) to cardiovascular risk factors and an increased risk of developing cardiovascular disease. Chronic inflammation, with shared pathways and cytokines common to metabolic syndrome, atherosclerosis and psoriasis, might provide the basis for the cardiovascular and metabolic comorbidities of psoriasis and PsA. The purpose of this manuscript is to review recent evidence about the epidemiology and underlying mechanisms of cardiovascular risk factors and cardiovascular disease in patients with psoriasis and/or PsA; the use of analytical determinations, physiologic measures and imaging techniques as surrogate biomarkers of atherosclerosis, endothelial dysfunction and cardiovascular disease in these patients; and the epidemiological and clinical data, including results of clinical trials, supporting a cardioprotective role of anti-inflammatory and disease-modifying treatment in psoriasis and PsA.https://www.mdpi.com/1422-0067/19/1/58psoriasispsoriatic arthritisinflammationcardiovascular diseasecardiovascular riskmetabolic syndromeatherosclerosis
collection DOAJ
language English
format Article
sources DOAJ
author Lluís Puig
spellingShingle Lluís Puig
Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis
International Journal of Molecular Sciences
psoriasis
psoriatic arthritis
inflammation
cardiovascular disease
cardiovascular risk
metabolic syndrome
atherosclerosis
author_facet Lluís Puig
author_sort Lluís Puig
title Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis
title_short Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis
title_full Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis
title_fullStr Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis
title_full_unstemmed Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis
title_sort cardiometabolic comorbidities in psoriasis and psoriatic arthritis
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2017-12-01
description There is solid epidemiologic evidence linking psoriasis and psoriatic arthritis (PsA) to cardiovascular risk factors and an increased risk of developing cardiovascular disease. Chronic inflammation, with shared pathways and cytokines common to metabolic syndrome, atherosclerosis and psoriasis, might provide the basis for the cardiovascular and metabolic comorbidities of psoriasis and PsA. The purpose of this manuscript is to review recent evidence about the epidemiology and underlying mechanisms of cardiovascular risk factors and cardiovascular disease in patients with psoriasis and/or PsA; the use of analytical determinations, physiologic measures and imaging techniques as surrogate biomarkers of atherosclerosis, endothelial dysfunction and cardiovascular disease in these patients; and the epidemiological and clinical data, including results of clinical trials, supporting a cardioprotective role of anti-inflammatory and disease-modifying treatment in psoriasis and PsA.
topic psoriasis
psoriatic arthritis
inflammation
cardiovascular disease
cardiovascular risk
metabolic syndrome
atherosclerosis
url https://www.mdpi.com/1422-0067/19/1/58
work_keys_str_mv AT lluispuig cardiometaboliccomorbiditiesinpsoriasisandpsoriaticarthritis
_version_ 1725499505360502784